First clinical multicenter experience with the new Pipeline Vantage flow diverter

Basit Öğe Kaydı
dc.contributor.authorVollherbst, Dominik F.
dc.contributor.authorCekirge, H. Saruhan
dc.contributor.authorSaatci, Isil
dc.contributor.authorBaltacioglu, Feyyaz
dc.contributor.authorOnal, Baran
dc.contributor.authorKoc, Osman
dc.contributor.authorRautio, Riitta
dc.date.accessioned2024-02-23T14:26:13Z
dc.date.available2024-02-23T14:26:13Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractBackground Flow diversion is an innovative and increasingly used technique for the treatment of intracranial aneurysms. New flow diverters (FDs) are being introduced to improve the safety and efficacy of this treatment. The aim of this study was to assess the safety, feasibility, and efficacy of the new Pipeline Vantage (PV) FD. Methods Patients with intracranial aneurysms treated with the PV at 10 international neurovascular centers were retrospectively analyzed. Patient and aneurysm characteristics, procedural parameters, complications, and the grade of occlusion were assessed. Results 60 patients with 70 aneurysms (5.0% with acute hemorrhage, 90.0% located in the anterior circulation) were included. 82 PVs were implanted in 61 treatment sessions. The PV could be successfully implanted in all treatments. Additional coiling was performed in 18.6%, and in-stent balloon angioplasty (to enhance the vessel wall apposition) in 24.6%. Periprocedural technical complications occurred in 24.6% of the treatments, were predominantly FD deployment problems, and were all asymptomatic. The overall symptomatic complication rate was 8.2% and the neurological symptomatic complication rate was 3.3%. Only one symptomatic complication was device-related (perforator artery infarctions leading to stroke). After a mean follow-up of 7.1 months, the rate of complete aneurysm occlusion was 77.9%. One patient (1.7%) died due to aneurysmal subarachnoid hemorrhage which occurred before treatment, unrelated to the procedure. Conclusions The new PV FD is safe and feasible for the treatment of intracranial aneurysms. The short-term occlusion rates are promising but need further assessment in prospective long-term follow-up studies.en_US
dc.identifier.doi10.1136/neurintsurg-2021-018480
dc.identifier.endpage69en_US
dc.identifier.issn1759-8478
dc.identifier.issn1759-8486
dc.identifier.issue1en_US
dc.identifier.pmid35172983en_US
dc.identifier.scopus2-s2.0-85142519353en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage63en_US
dc.identifier.urihttps://doi.org/10.1136/neurintsurg-2021-018480
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14111
dc.identifier.volume15en_US
dc.identifier.wosWOS:000757528500001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofJournal Of Neurointerventional Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAneurysmen_US
dc.subjectFlow Diverteren_US
dc.subjectAngiographyen_US
dc.subjectInterventionen_US
dc.titleFirst clinical multicenter experience with the new Pipeline Vantage flow diverteren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu